Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
$3.30
-1.2%
$2.64
$1.58
$11.99
$79.19M0.92217,285 shs69,791 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$5.34
+6.4%
$4.71
$3.90
$15.00
$63.33M0.52268,805 shs289,467 shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.40
-2.1%
$1.42
$1.17
$1.96
$70.39M0.6325,216 shs15,710 shs
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
$3.36
+3.7%
$2.81
$1.83
$30.80
$17.32M1.0182,100 shs25,188 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
0.00%+13.61%+73.96%-24.26%-64.09%
Lifevantage Corporation stock logo
LFVN
Lifevantage
0.00%-0.59%+23.34%-0.20%-55.10%
MediciNova, Inc. stock logo
MNOV
MediciNova
0.00%+2.88%-0.69%-10.63%-4.03%
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
0.00%-26.53%+52.11%+16.97%-80.94%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
$3.30
-1.2%
$2.64
$1.58
$11.99
$79.19M0.92217,285 shs69,791 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$5.34
+6.4%
$4.71
$3.90
$15.00
$63.33M0.52268,805 shs289,467 shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.40
-2.1%
$1.42
$1.17
$1.96
$70.39M0.6325,216 shs15,710 shs
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
$3.36
+3.7%
$2.81
$1.83
$30.80
$17.32M1.0182,100 shs25,188 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
0.00%+13.61%+73.96%-24.26%-64.09%
Lifevantage Corporation stock logo
LFVN
Lifevantage
0.00%-0.59%+23.34%-0.20%-55.10%
MediciNova, Inc. stock logo
MNOV
MediciNova
0.00%+2.88%-0.69%-10.63%-4.03%
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
0.00%-26.53%+52.11%+16.97%-80.94%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
2.33
Hold$17.50430.30% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
2.00
Hold$5.00-6.37% Downside
MediciNova, Inc. stock logo
MNOV
MediciNova
2.86
Moderate Buy$7.50435.71% Upside
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest NCEL, LFVN, MNOV, and ACTU Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
DowngradeBuyHold$5.00
5/4/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
DowngradeHold (C)Hold (C-)
5/4/2026
MediciNova, Inc. stock logo
MNOV
MediciNova
Reiterated RatingBuy$9.00
4/22/2026
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
Reiterated RatingBuy$15.00
4/13/2026
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
Lower Price TargetBuy$20.00 ➝ $15.00
3/27/2026
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
Reiterated RatingSell (E+)
3/27/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
Reiterated RatingHold (C)
3/27/2026
MediciNova, Inc. stock logo
MNOV
MediciNova
Reiterated RatingSell (D-)
3/23/2026
MediciNova, Inc. stock logo
MNOV
MediciNova
Reiterated RatingBuy$6.00
3/17/2026
MediciNova, Inc. stock logo
MNOV
MediciNova
UpgradeHold
3/16/2026
MediciNova, Inc. stock logo
MNOV
MediciNova
Initiated CoverageBuy$10.00
(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
N/AN/AN/AN/A$0.34 per shareN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$228.53M0.29$1.17 per share4.57$2.64 per share2.02
MediciNova, Inc. stock logo
MNOV
MediciNova
$410K168.07N/AN/A$0.85 per share1.65
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
N/AN/AN/AN/A$1.59 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
-$22.23M-$1.05N/AN/AN/AN/A-799.68%-205.80%N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$9.81M$0.4511.877.63N/A2.94%23.89%12.47%N/A
MediciNova, Inc. stock logo
MNOV
MediciNova
-$12M-$0.24N/AN/AN/AN/A-26.32%-24.55%5/13/2026 (Estimated)
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
-$8.30MN/AN/AN/AN/AN/AN/AN/AN/A

Latest NCEL, LFVN, MNOV, and ACTU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026N/A
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.06N/AN/AN/A$0.13 millionN/A
5/6/2026Q3 2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.12-$0.04$0.11$47.77 million$43.72 million
3/26/2026Q4 2025
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
-$0.24-$0.18+$0.06-$0.18N/AN/A
2/20/2026Q4 2025
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.0950-$0.05+$0.0450-$0.05N/A$0.15 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.183.37%N/A40.00%3 Years
MediciNova, Inc. stock logo
MNOV
MediciNova
N/AN/AN/AN/AN/A
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
N/AN/AN/AN/AN/A

Latest NCEL, LFVN, MNOV, and ACTU Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/27/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.054%6/1/20266/1/20266/15/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
N/A
2.39
2.39
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.96
1.03
MediciNova, Inc. stock logo
MNOV
MediciNova
N/A
8.16
8.16
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
N/A
0.76
0.76

Institutional Ownership

CompanyInstitutional Ownership
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
MediciNova, Inc. stock logo
MNOV
MediciNova
9.90%
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
N/A

Insider Ownership

CompanyInsider Ownership
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
57.98%
Lifevantage Corporation stock logo
LFVN
Lifevantage
21.95%
MediciNova, Inc. stock logo
MNOV
MediciNova
13.60%
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
16.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
1023.71 million9.96 millionN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.62 million9.99 millionOptionable
MediciNova, Inc. stock logo
MNOV
MediciNova
1049.22 million42.53 millionOptionable
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
65.35 million4.47 millionNot Optionable

Recent News About These Companies

NewCelX Appoints EY as New Auditor Following Merger
NewcelX Ltd.
NewcelX CEO Issues Letter to Shareholders

New MarketBeat Followers Over Time

Media Sentiment Over Time

Actuate Therapeutics stock logo

Actuate Therapeutics NASDAQ:ACTU

$3.30 -0.04 (-1.20%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$3.32 +0.02 (+0.61%)
As of 05/8/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$5.34 +0.32 (+6.37%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$5.30 -0.04 (-0.75%)
As of 05/8/2026 06:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

MediciNova stock logo

MediciNova NASDAQ:MNOV

$1.40 -0.03 (-2.10%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$1.41 +0.01 (+0.71%)
As of 05/8/2026 06:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

NLS Pharmaceutics stock logo

NLS Pharmaceutics NASDAQ:NCEL

$3.36 +0.12 (+3.70%)
As of 05/8/2026 04:00 PM Eastern

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.